PARP inhibition in cancer therapy
PARP inhibition in cancer therapy is a topic indexed in ScholarIQ from OpenAlex.
What is known about PARP inhibition in cancer therapy?
This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored.
How many works does PARP inhibition in cancer therapy have?
PARP inhibition in cancer therapy has 42,256 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does PARP inhibition in cancer therapy have?
PARP inhibition in cancer therapy has 663,289 citations in the OpenAlex counts ScholarIQ stores.
What is the OpenAlex record for PARP inhibition in cancer therapy?
The OpenAlex for PARP inhibition in cancer therapy is on the source record.